Omeros

Omeros is a Seattle-based commercial-stage biopharmaceutical company that discovers, develops, and commercializes first-in-class small-molecule and protein therapeutics for large-market and orphan indications. Its programs focus on complement-mediated diseases, inflammation, cancers, and addictive or compulsive disorders. The company’s pipeline includes FDA-approved YARTEMLEA, the investigational MASP-2 inhibitor OMS1029, OMS527 in clinical development, and a growing portfolio of molecular and cellular oncology programs.